Status:
COMPLETED
Relative Oral Bioavailability of Telmisartan / Hydrochlorothiazide (HCTZ) Fixed Dose Combination (FDC) Compared With Its Monocomponents in Healthy Subjects
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
A study to demonstrate the bioequivalence of telmisartan and HCTZ administered as fixed dose combination in comparison to the single unit formulations
Eligibility Criteria
Inclusion
- Healthy subjects as determined by results of screening
- Signed written informed consent in accordance with good clinical practice (GCP) and local legislation
- Age ≥ 18 and ≤ 55 years
- Broca ≥ -20 % and ≤ +20 %
Exclusion
- Any findings of the medical examination (including blood pressure, pulse rate and electrocardiogram (ECG)) deviating from normal and of clinical relevance
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Surgery of the gastro-intestinal tract (except appendectomy)
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- Supine blood pressure at screening of systolic ≤ 110 mmHg and diastolic ≤ 60 mmHg
- History of orthostatic hypotension, fainting, spells or blackouts
- Chronic or relevant acute infection
- History or allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- Intake of drugs with a long half-life (\> 24 hours) ≤ 1 month prior to administration or during the trial
- Use of any drugs which might influence the results of the trial (≤ 10 days prior to administration or during the trial)
- Participation in another trial with an investigational drug (≤ 2 months prior to administration or during the trial)
- Smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day)
- Inability to refrain from smoking on study days
- Alcohol abuse (\> 60g/day)
- Drug abuse
- Blood donation (≤ 1 month prior to administration or during the trial)
- Excessive physical activities (≤ 5 days prior to administration or during the trial)
- Any laboratory value outside the reference range of clinical relevance
- Hypersensitivity to Telmisartan and/or HCTZ and/or related classes of drugs
- For female subjects:
- Pregnancy
- Positive pregnancy test
- No adequate contraception (e.g. sterilization, intrauterine device (IUD), oral contraceptives)
- Inability to maintain this adequate contraception during the whole study period
- Lactation period
Key Trial Info
Start Date :
October 1 1999
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT02187523
Start Date
October 1 1999
Last Update
July 11 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.